First Trust Advisors’s Co-Diagnostics CODX Stock Holding History

First Trust Advisors’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,706	Closed	-$90.1K	–	2382
2023 Q2	$90.1K	Sell	2,706 -38	-1%	-$1.45K	﹤0.01%	2337
2023 Q1	$122K	Buy	2,744 +209	+8%	+$16.8K	﹤0.01%	2332
2022 Q4	$192K	Sell	2,535 -427	-14%	-$40K	﹤0.01%	2376
2022 Q3	$285K	Buy	2,962 +1,373	+86%	+$192K	﹤0.01%	2336
2022 Q2	$267K	Buy	1,589 +188	+13%	+$28.6K	﹤0.01%	2329
2022 Q1	$260K	Sell	1,401 -67	-5%	-$13.9K	﹤0.01%	2406
2021 Q4	$393K	Buy	1,468 +181	+14%	+$47.5K	﹤0.01%	2346
2021 Q3	$376K	Buy	+1,287	New	+$376K	﹤0.01%	2341

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.3B AUM 18.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

First Trust Advisors's CODX Position: Q3 2023 in Review

First Trust Advisors sold out of Co-Diagnostics (CODX) in Q3 2023, closing a stake of 2,706 shares — an estimated $90.1K sold.

First Trust Advisors first reported a position in CODX in Q3 2021 and held it in 8 quarters. The position peaked at $393K in Q4 2021. 43 funds tracked by Wall St. Rank hold CODX as of Q3 2023.

First Trust Advisors reported no remaining Co-Diagnostics position as of Q3 2023 after selling out during the quarter.
First Trust Advisors sold 2,706 Co-Diagnostics shares in Q3 2023, an estimated $90.1K.
First Trust Advisors first reported a position in Co-Diagnostics in Q3 2021 and held it in 8 quarters.
First Trust Advisors's Co-Diagnostics position peaked at $393K in Q4 2021.
43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.